PMID- 27206144
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160524
LR  - 20160521
IS  - 2160-763X (Print)
IS  - 2160-763X (Linking)
VI  - 1
IP  - 1
DP  - 2012 Jan
TI  - Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic 
      Moxidectin.
PG  - 32-7
LID - 10.1177/2160763X11432508 [doi]
AB  - The antiparasitic agent moxidectin is under development for the treatment of 
      onchocerciasis. As the first-in-human study of moxidectin used a liquid 
      formulation but other trials used tablets, a study was performed to determine the 
      relative bioavailability of the 2 formulations and to gain more information about 
      the pharmacokinetics of moxidectin. Fifty-eight healthy male participants were 
      randomized to receive open-label moxidectin (10 mg) as a tablet (n = 29) or 
      liquid (n = 29) formulation. The mean +/- SD pharmacokinetic parameters observed 
      following administration of the tablet were peak concentration (Cmax) 67.1 +/- 27.4 
      ng/mL, time to peak concentration (tmax) 3.2 +/- 1.4 hours, area under the 
      concentration time curve (AUC) 4403 +/- 2360 ng.h/mL, apparent volume of 
      distribution 3635 +/- 1720 L, oral clearance 2.83 +/- 1.25 L/h, and elimination 
      half-life 1032 +/- 502 hours. The Cmax and AUC observed following administration of 
      the liquid formulation were 28.6% and 28.8% higher, respectively, and tmax 0.9 
      hours shorter compared with tablets. No serious adverse events (AEs) were 
      observed. The most commonly reported AEs were headache, infection, diarrhea, 
      asthenia, myalgia, and dizziness during the inpatient phase and flu syndrome, 
      headache, and infection during the 6-month outpatient phase. There was no 
      difference in reporting of these AEs between formulations.
CI  - 2012 American College of Clinical Pharmacology.
FAU - Korth-Bradley, Joan M
AU  - Korth-Bradley JM
AD  - Clinical Pharmacology, Pfizer Inc, Collegeville, PA, USAPfizer Global Research 
      and Development, Paris/La Defense, FranceClinical Pharmacology, Wyeth Research, 
      Paris, FranceCollege of Pharmacy, University of Iowa, Iowa City, IA, USA.
FAU - Parks, Virginia
AU  - Parks V
AD  - Clinical Pharmacology, Pfizer Inc, Collegeville, PA, USAPfizer Global Research 
      and Development, Paris/La Defense, FranceClinical Pharmacology, Wyeth Research, 
      Paris, FranceCollege of Pharmacy, University of Iowa, Iowa City, IA, USA.
FAU - Patat, Alain
AU  - Patat A
AD  - Clinical Pharmacology, Pfizer Inc, Collegeville, PA, USAPfizer Global Research 
      and Development, Paris/La Defense, FranceClinical Pharmacology, Wyeth Research, 
      Paris, FranceCollege of Pharmacy, University of Iowa, Iowa City, IA, USA.
FAU - Matschke, Kyle
AU  - Matschke K
AD  - Clinical Pharmacology, Pfizer Inc, Collegeville, PA, USAPfizer Global Research 
      and Development, Paris/La Defense, FranceClinical Pharmacology, Wyeth Research, 
      Paris, FranceCollege of Pharmacy, University of Iowa, Iowa City, IA, USA.
FAU - Mayer, Philip
AU  - Mayer P
AD  - Clinical Pharmacology, Pfizer Inc, Collegeville, PA, USAPfizer Global Research 
      and Development, Paris/La Defense, FranceClinical Pharmacology, Wyeth Research, 
      Paris, FranceCollege of Pharmacy, University of Iowa, Iowa City, IA, USA.
FAU - Fleckenstein, Lawrence
AU  - Fleckenstein L
AD  - Clinical Pharmacology, Pfizer Inc, Collegeville, PA, USAPfizer Global Research 
      and Development, Paris/La Defense, FranceClinical Pharmacology, Wyeth Research, 
      Paris, FranceCollege of Pharmacy, University of Iowa, Iowa City, IA, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Drug Dev
JT  - Clinical pharmacology in drug development
JID - 101572899
OTO - NOTNLM
OT  - antiparasitic
OT  - bioavailability
OT  - moxidectin
OT  - onchocerciasis
OT  - pharmacokinetics
EDAT- 2012/01/01 00:00
MHDA- 2012/01/01 00:01
CRDT- 2016/05/21 06:00
PHST- 2016/05/21 06:00 [entrez]
PHST- 2012/01/01 00:00 [pubmed]
PHST- 2012/01/01 00:01 [medline]
AID - 10.1177/2160763X11432508 [doi]
PST - ppublish
SO  - Clin Pharmacol Drug Dev. 2012 Jan;1(1):32-7. doi: 10.1177/2160763X11432508.